Oral Lactobacillus reuteri Combined With Intravenous Lysis‐Circuit‐Bearing Engineered Bacteria RE Enhances Antitumor Efficacy
Biotechnology Journal · 2026-05 · 21 (5)
DOI: 10.1002/biot.70243 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology Journal, online erschienen am 19.05.2026. Verfasst von Feng Geng und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Shandong Medical and Pharmaceutical University, Yantai, China. Hauptthemen laut MEDLINE: Limosilactobacillus reuteri, Probiotics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Key Research and Development Program of Shandong Province, Yantai Scientific and Technological Innovation Development Plan, Yantai Natural Science Foundation Project.
Abstract (Originalsprache)
Engineered bacteria can preferentially colonize hypoxic tumors, but improving efficacy while limiting systemic bacterial burden remains a central challenge. Here, we combined oral Lactobacillus reuteri (LR) with intravenous administration of RE, an engineered Escherichia coli Rosetta strain carrying the quorum‐sensing lysis plasmid pTD103‐E. This circuit couples LuxI/R‐mediated population sensing to expression of the phage lysis gene φX174 E and was designed to enable density‐associated bacterial lysis. In a 4T1 mouse model, LR+RE improved antitumor efficacy by 45% compared with single‐bacterium treatment. RE remained enriched in tumors while being cleared from major organs within 72 h. Combined treatment increased intratumoral IFN‐γ, altered IL‐12 expression, elevated AhR abundance in tumor tissues, and increased CD8+ T‐cell infiltration. These changes were accompanied by polarization of tumor‐associated macrophages toward an M1‐like phenotype, suppression of M2‐like features, and increased markers of cell‐cycle arrest and apoptosis. Fecal 16S rRNA profiling further showed that treatment reshaped the gut microbiota and identified Prevotellaceae_NK3B31_group as a microbial taxon associated with IFN‐γ‐centered antitumor responses. Together, these findings indicate that a natural probiotic can potentiate a tumor‐targeted engineered bacterial therapy and is associated with coordinated microbiota‐immune remodeling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Shandong Medical and Pharmaceutical University, Yantai, China.
- Shandong Guohetang Pharmaceutical Co., Ltd, Zhongke Aiwei Biotechnology Co., Ltd, Yantai, Shandong, China.
- Shandong Provincial Engineering Research Center for Probiotic Functional Nutrition and Special Medical Foods, Yantai Key Laboratory of Microecological Precision Nutrition and Health, Yantai, Shandong, China.
Förderung
- Key Research and Development Program of Shandong Province
- Yantai Scientific and Technological Innovation Development Plan
- Yantai Natural Science Foundation Project
- "Double Hundred Plan" High-End Talent Project of Yantai City
- Key Technology Research and Development Program of Shandong Province
Zitieren
APA
Geng, F., Yue, L., Du, M., Jin, J., Zhang, Q., Hu, W., Hao, N., Liu, S., Jiang, P., & Pan, X. (2026). Oral Lactobacillus reuteri Combined With Intravenous Lysis‐Circuit‐Bearing Engineered Bacteria RE Enhances Antitumor Efficacy. Biotechnology Journal, 21(5). https://doi.org/10.1002/biot.70243
Vancouver
Geng F, Yue L, Du M, Jin J, Zhang Q, Hu W, et al. Oral Lactobacillus reuteri Combined With Intravenous Lysis‐Circuit‐Bearing Engineered Bacteria RE Enhances Antitumor Efficacy. Biotechnology Journal. 2026;21(5). doi:10.1002/biot.70243
BibTeX
@article{Geng2026,
author = {Geng, Feng and Yue, Lijun and Du, Maoru and Jin, Jiayi and Zhang, Qiongwen and Hu, Wenxin and Hao, Na and Liu, Sitong and Jiang, Peilin and Pan, Xiaohong},
title = {Oral Lactobacillus reuteri Combined With Intravenous Lysis‐Circuit‐Bearing Engineered Bacteria RE Enhances Antitumor Efficacy},
journal = {Biotechnology Journal},
year = {2026},
volume = {21},
number = {5},
doi = {10.1002/biot.70243}
}
EUVIMED